Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20515258 | 0.75 | RAB9A (0.47) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20515283 | 0.73 | MAPT (0.43) | HPGDALDH1A1 | |
| SCHEMBL20515253 | 0.73 | PTK2 (0.41) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20514025 | 0.72 | GAA (0.58) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20515292 | 0.72 | HPGD (0.52) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20515251 | 0.71 | HPGD (0.50) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20515254 | 0.71 | MAPT (0.54) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20515268 | 0.70 | GAA (0.53) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20515252 | 0.69 | POLB (0.43) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 | |
| SCHEMBL20514178 | 0.69 | SMN1; SMN2 (0.57) | KMT2ASMN1; SMN2HPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | KMT2A 1425/4885SMN1; SMN2 4614/4885HPGD 4292/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | KMT2A 1425/4885SMN1; SMN2 4614/4885HPGD 4292/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | KMT2A 1354/4885SMN1; SMN2 4552/4885HPGD 4302/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | KMT2A 1359/4885SMN1; SMN2 4490/4885HPGD 4319/4885 |
| US-20180282289-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | KMT2A 1309/4885SMN1; SMN2 4501/4885HPGD 4280/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | KMT2A 1383/4885SMN1; SMN2 4618/4885HPGD 4244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.